Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00
Provider: Wright Reports
$357.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

IntegraGen SA Announces Publication of the Result of International Study with Its Five-gene Prognostic Molecular Signature


Monday, 8 Jul 2013 11:30am EDT 

IntegraGen SA announced the publication of a study in the online edition of Gastroenterology reporting results with its five-gene expression molecular signature. The study authors report that the molecular signature demonstrates the ability to accurately predict the clinical prognosis of patients with a primary liver cancer (hepatocellular carcinoma) and in whom surgical resection of the affected part of the liver is being considered. The signature allows for the determination of which patients will likely benefit the most from the surgery. The publication, based on a study of 738 patients, details the identification and replication of a five-gene molecular prognostic signature in a cohort of 179 HCC patients treated in French hospitals at Bordeaux and Creteil (Henri Mondor Hospital, AP-HP) and the validation of this signature in 559 HCC patients representing independent patient cohorts from France, Spain, Italy, Japan, China, and the United States. The five-gene score was found to more accurately predict HCC patient outcomes than gene expression signatures previously reported. In multivariate analyses, the five-gene score was shown to be associated with disease-specific survival, independent of other clinical and pathology feature of HCC. 

Company Quote

5.54
-0.08 -1.42%
29 Aug 2014